Benzinga · Feb 19, 2026
Guggenheim Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $45
Guggenheim analyst Debjit Chattopadhyay maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $41 to $45.
NA
NASDAQ · NAMS
NewAmsterdam Pharma Company N.V.
Healthcare · Biotechnology
$21.93
Up+$0.75 (+3.54%)
Updated Sep 18, 2026, 2:20 AM
SID Score
3.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.1B
- P/E ratio
- -19.49
- Dividend yield
- 0.00%
- 52-week range
- $21.02 – $42.21
- Volume
- 2.31M
- Avg. volume
- 1.15M
Price performance
NAMS price history
1M range · 0 trading sessions · Daily adjusted prices
NAMS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest NAMS news
The latest Smart Investors Daily articles mentioning NAMS.
Stock researchCompany · Overview
NAMS research
Overview
Company profile and research snapshot.
Company profile
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $44.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Jun 30, 2026 | RBC Capital | Outperform | — |
| Feb 19, 2026 | Guggenheim | Buy | — |
| Feb 18, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 18, 2026
Forecasting The Future: 4 Analyst Projections For NewAmsterdam Pharma Co
Benzinga · Feb 18, 2026
Needham Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $48
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $46 to $48.
Yahoo · Feb 18, 2026
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinded event rate tracking in line with observed event rate in BROADWAY-- -- Topline data from RUBENS Phase 3 trial in patients with type 2 diabetes and metabolic syndrome expected by year-end 2026 -- -- $728.9 million in cash, cash equivalents and marketable securities at December 31, 2025 -- NAARDEN, the Netherlands and MIAM
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
